Gene Expression Profiling in Wild-Type and PPAR𝛼-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPAR𝛼-Independent Effects

Table 4

Average fold change for genes related to proteasome biogenesis in wild-type and PPAR$\alpha$-null male mice following a seven-day exposure to Wy-14,64$3^1$, PFOA¹, or PFOS.

					WT			Null
Symbol	Gene name	Entrez no.	Wy14,643 50 mg/kg	PFOA 3 mg/kg	PFOS 3 mg/kg	PFOS 10 mg/kg	PFOA 3 mg/kg	PFOS 3 mg/kg	PFOS 10 mg/kg
PSMA1	proteasome unit,; alpha type, 1	26440	1.61	1.38	1.15	1.31*	1.17	−1.29	−1.34
PSMA2	proteasome unit,; alpha type, 2	19166	−1.46	−1.15	1.09	1.23**	−1.34	−1.20	−1.07
PSMA3	proteasome unit,; alpha type, 3	19167	1.33	1.22	1.12	1.14	1.28	−1.13	−1.17
PSMA4	proteasome unit,; alpha type, 4	26441	1.19	1.32	1.10	1.19*	1.01	−1.04	1.05
PSMA5	proteasome unit,; alpha type, 5	26442	1.67	1.59	1.12	1.26**	1.15	−1.12	1.09
PSMA6	proteasome unit,; alpha type, 6	26443	1.20	1.29	1.14	1.24**	1.06	−1.14	−1.06
PSMA7	proteasome unit,; alpha type, 7	26444	1.47	1.60	1.23	1.53**	1.23	−1.12	1.11
PSMB1	proteasome unit,; beta type, 1	19170	1.09	1.29	1.07	1.28*	1.04	−1.17	1.13*
PSMB10	proteasome unit,; beta type, 10	19171	−1.42	−1.48	−1.25	−1.19	−1.57	−1.14	−1.21**
PSMB2	proteasome unit,; beta type, 2	26445	1.33	1.48	1.05	1.31**	1.02	−1.20	1.05
PSMB3	proteasome unit,; beta type, 3	26446	1.22	1.47	1.21	1.36**	1.04	−1.37	−1.20
PSMB4	proteasome unit,; beta type, 4	19172	1.59	1.65	1.27	1.55**	1.22	−1.12	1.09
PSMB5	proteasome unit,; beta type, 5	19173	1.34	1.74	1.04	1.24**	1.02	−1.15	1.03
PSMB6	proteasome unit,; beta type, 6	19175	1.54	1.83	1.08	1.24*	1.19	−1.23	−1.09
PSMB7	proteasome unit,; beta type, 7	19177	1.46	1.33	1.07	1.15**	1.13	−1.17	−1.09
PSMB8	proteasome unit,; beta type, 8	16913	−1.61	−2.00	−1.44	−1.51	−1.38	−1.23	−1.45**
PSMB9	proteasome unit,; beta type, 9	16912	1.24	−1.12	−1.31	−1.09	−1.10	−1.11	−1.30**
PSMC1	proteasome 26S unit,; ATPase, 1	19179	1.44	1.00	1.19	1.15*	1.11	−1.06	1.01
PSMC6	proteasome 26S unit,; ATPase, 6	67089	1.18	1.21	1.09	−1.02	1.07	1.14	−1.16
PSMD1	proteasome 26S unit,; non-ATPase, 1	70247	1.20	1.22	1.15	1.25**	1.09	1.03	1.15
PSMD11	proteasome 26S unit,; non-ATPase, 11	69077	1.56	1.38	1.09	1.26*	−1.17	1.16	1.32
PSMD12	proteasome 26S unit,; non-ATPase, 12	66997	1.34	1.27	1.10	1.14	1.20	−1.03	1.04
PSMD13	proteasome 26S unit,; non-ATPase, 13	23997	1.21	1.38	1.14	1.26*	−1.03	−1.38	−1.42**
PSMD14	proteasome 26S unit,; non-ATPase, 14	59029	−1.39	−1.42	1.17	1.31*	1.31	1.01	1.17
PSMD2	proteasome 26S unit,; non-ATPase, 2	21762	1.34	1.32	1.14	1.24*	1.10	1.09	1.30**
PSMD3	proteasome 26S unit,; non-ATPase, 3	22123	−1.35	−1.19	1.17	1.29*	1.08	1.04	1.22*
PSMD4	proteasome 26S unit,; non-ATPase, 4	19185	1.31	1.92	1.19	1.38**	1.03	−1.07	1.17*
PSMD6	proteasome 26S unit,; non-ATPase, 6	66413	1.17	1.33	1.10	1.14*	1.07	−1.06	1.04
PSMD7	proteasome 26S unit,; non-ATPase, 7	17463	1.13	1.27	1.13	1.24*	1.02	−1.19	−1.22*
PSMD8	proteasome 26S unit,; non-ATPase, 8	57296	1.68	1.24	1.03	1.30**	1.16	−1.15	−1.00
PSME1	proteasome activator; unit 1	19186	1.22	−1.00	−1.05	1.32**	1.27	−1.10	−1.09
VCP	valosin−containing; protein	269523	1.40	1.49	1.04	1.12	1.07	1.13	1.21**

¹From Rosen et al. (2008),
*Significantly different than control ($P\le .03$),
**Significantly different than control ($P\le .0025$).